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The group of idiopathic epilepsies encompasses numerous syndromes without known organic substrate.
Genetic anomalies are thought to be responsible for pathogenesis, with a monogenic or polygenic model
of inheritance. Over the last two decades, a number of genetic anomalies and encoded proteins have been
related to particular idiopathic epilepsies and epileptic encephalopathies. Most of these mutations
involve subunits of neuronal ion channels (e.g. potassium, sodium, and chloride channels), and may
result in abnormal neuronal hyperexcitability manifesting with seizures. However non-ion channel
proteins may also be affected. Correlations between genotype and phenotype are not easy to establish,
since genetic and non-genetic factors are likely to play a role in determining the severity of clinical
features. The growing number of discoveries on this topic are improving classiﬁcation, prognosis and
counseling of patients and families with these forms of epilepsy, and may lead to targeted therapeutic
approaches in the near future. In this article the authors have reviewed the main genetic discoveries in
the ﬁeld of the monogenic idiopathic epilepsies and epileptic encephalopathies, in order to provide
epileptologists with a concise and comprehensive summary of clinical and genetic features of these
seizure disorders.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Idiopathic epilepsies represent up to 47% of all epilepsies, and
they are thought to have a genetic origin with a monogenic or
polygenic model of inheritance. During the last 2 decades, several
epilepsy-causing gene mutations have been discovered, improving
our knowledge on the classiﬁcation of epilepsies and epileptic
encephalopathies and the epileptogenicmechanisms and therapeu-
tic approaches. However, to date, only about 2% of the idiopathic
epilepsies are considered tobemonogenic, andnumerous issues still
remain unclear.1 In majority of the monogenic epilepsies (Table 1),
the mutated genes encode ion channel subunits (Table 2) (e.g.,
voltage-gated sodium and potassium channel subunits) that
mediate neuronal excitability and whose gain or loss of function
result in abnormal generation andpropagation of action potentials.2
However, epilepsy-causing genes coding for non-ion channel
proteins have been mapped (Table 2); in these cases, identiﬁcation* Corresponding author at: Department of Pediatrics, Child Neurology Division
‘‘Sapienza’’ Roma, Viale Regina Elena 324 00161 Roma, Italy. Tel.: +39 06 49979311;
fax: +39 06 49979312.
E-mail address: childneurology.sapienzaroma@live.it (A. Spalice).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.08.007of epileptogenic mechanisms responsible for seizure induction is
less clear and functional interaction with ion channels is supposed.
Genotype–phenotype correlations have not been completely clari-
ﬁed, since several undeﬁned genetic and environmental factors are
thought to play a role in determining the phenotype: some epileptic
syndromes, in particular the group of idiopathic generalised
epilepsies, may have complex polygenetic traits; furthermore,
monogenic epilepsy syndromes may have been derived from
mutations of different genes.1 Finally, a speciﬁc mutation (e.g.,
missense sodium channel alpha 1 subunit [SCN1A] mutations) may
underlie more phenotypes (from febrile seizures plus to the Dravet
syndrome [DS]), but a speciﬁc phenotype may also be derived from
different mutations on a single gene (e.g., missense or nonsense or
other type of SCN1Amutations). In this article,wehave reviewed the
main genetic discoveries in the ﬁeld of monogenic idiopathic
epilepsies and epileptic encephalopathies to provide epileptologists
a rapid and comprehensive summary of the clinical and genetic
features of these forms.
2. Early infantile epileptic encephalopathy/ohtahara syndrome
Early infantile epileptic encephalopathy (EIEE) (OMIM
#308350), also known as the Ohtahara syndrome (OS),3 isvier Ltd. All rights reserved.
Table 1
Monogenic epileptic syndromes and encephalopathies. List of abbreviation: PB, phenobarbital; ACTH, adrenocorticotropic hormone; VPA valproic acid; CBZ, clobazam; CZP,
clonazepam; GVG, vigabatrin; ESM, ethosuximide; LZP, lorazepam; PHT, phenytoin; LEV, levitiracetam; TPM, topiramate; CBZ, carbamazepine; LTG, lamotrigine; ZNS,
zonisamide; IVIG, intra venous immunoglobulin.
Syndrome Age of onset Seizure type Inter-ictal EEG features Therapeutic options
EME Neonatal period Fragmentary and erratic myoclonias, simple
partial seizures, massive myoclonus, tonic spasms
Suppression burst pattern PB, steroids, ACTH,
other AEDs
EIEE-OS Neonatal period –
ﬁrst months of life
Tonic spasms, erratic focal motor seizures,
generalized tonic seizures
Suppression burst pattern VPA, CBZ, CZP, GVG,
ACTH, Steroids, IVIG
BFNS
BFNIS
BFIS
First days of life
Neonatal period
3m-12m
Focal tonic–clonic convulsions,
generalized convulsions
Normal; focal or multifocal
abnormalities or ‘the´ta
pointu alternant’ pattern
PB
GEFS+ Early infancy or
childhood (6m-6y)
FS, FS+, GTCS, AbS, AtS, focal seizures, MyS Normal; focal or generalized
spike
and
waves complexes
VPA, ESM, CBZ, PB
DS Early infancy (before
1 year of age)
Febrile seizures, tonic–clonic,
tonic, atonic, absences,
myoclonic jerks, partial seizures
Normal during the ﬁrst 12m of life;
Focal or generalized spike and
waves complexes
VPA, PB, CPZ, LPZ,
ESM, PTH, STP
EFMR Early infancy or
childhood
(6-36m)
Febrile seizures, tonic–clonic, tonic,
atonic, absences, myoclonic jerks, partial seizures
Focal or multifocal or generalized
spike-and-wave complexes
VPA, PB, TPM,
LZP, CLB
ISSX Before 1 year of age Infantile spasms Hypsarrhythmia VPA, CBZ, LEV,
ESM, CLB, LTG
RTT After 2 year of age GTCS, absence seizures, myoclonic seizures,
tonic seizures, atonic seizures
Slow waves, focal or multifocal
paroxysmal activity
EOAE Before 4 year of age Absence seizures 3 Hz diffuse spike and waves complexes VPA, ESM
JME Late childhood–early
adulthood
Myoclonic seizures, GTCS, absence seizures Diffuse spike and waves
complexes; photosensitivity
VPA, CZP, TPM,
LTG, ZNS
ADPEAF/ADLTE 4–50 years Simple and/or complex focal (temporal seizures),
with or without secondary generalization
Normal or with epileptic anomalies
in temporal regions
VPA, CBZ, PHT
ADFNLE First two decade Nocturnal (and rarely daily) seizures
with frontal semiology
Normal (waking) or with epileptic anomalies
in frontal regions (sleep)
CBZ, ZNS
F. Nicita et al. / Seizure 21 (2012) 3–114characterised by the early onset of tonic spasms that occur with or
without clustering, seizure intractability, a characteristic interictal
suppression burst (SB) pattern on the EEG that is persistently
observed in both waking and sleeping states, and a remarkable
age-dependent evolution into the West syndrome (WS) (reported
in 75% of the cases).4 In addition to tonic spasms, partial seizures,
such as erratic focal motor seizures, are observed in about one-
third to one-half of the patients. Prognosis is very poor with severe
drug resistance and psychomotor retardation. The mortality rate isTable 2
Genes and encoded proteins involved in the genetic epileptic syndromes and encepha
Protein Subunit
Neuronal nicotinic acetylcholinic receptor a2-subunit
a4-subunit
b2-subunit
M-current protein channel Kv7.2
Kv7.3
Voltage gated Sodium channel a1-subunit
a2-subunit
b2-subunit
GABA receptor a1-subunit
g2-subunit
Leucine rich glioma inactivated 1
Glucose transporter type 1
EF hand motif containing 1
Protochaderin
Cyclin-dependent kinase-like 5
Aristaless related homeobox
Sintaxin binding protein 1
Solute carrier family 25 member 22high, especially in the early stage of the disorder.4 The causes of
EIEE are heterogeneous. Several brain malformations, neuronal
migration disorders, and metabolic disorders have been found as
the underlying causes of symptomatic OS.5 Two causative genes
are thought to be involved in the pathogenesis of the cryptogenic
cases of OS: the aristaless-related homeobox (ARX) and the
syntaxin-binding protein 1 (STXBP1) genes. The ARX gene is
considered to have an important role in neuronal proliferation,
differentiation of the embryonic brain, and interneuronal migra-lopathies.
Gene Gene locus Phenotype
CHRNA2 8p21 ADNFLE
CHRNA4 20q13 ADNFLE
CHRNB2 1q21 ADNFLE
KCNQ2 20q13 BFNS
KCNQ3 8q24 BFNS
SCN1A 2q24 GEFS+
SMEI
IGE-GTC
MAE
SCN2A 2q23-q24.3 BFNIS
BFIS
SMEI
SCN2B 19q13 GEFS+
EOAE+FS plus
GABRA1 5q34-q35 JME
GABRG2 5q34 GEFS+
CAE
LGI1 10q24 ADPEAF/ADLTE
SLC2A1 1p35-p31.3 EOAE
EFHC1 6p12-p11 JME
PCDH19 Xq22 EFMR
CDKL5/STK9 Xq28 ISSX-RTT
ARX Xp22.13 OS
STXBP1 (MUNC18-1) 9q34.1 OS
SLC25A22 11p15.5 EME
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aminobutyric acid (GABA)ergic interneurons.6 Phenotypes associ-
ated with ARX mutations include both malformative and non-
malformative syndromes. Malformation syndromes (e.g., X-linked
lissencephaly with an absent corpus callosum, the Proud
syndrome, X-linked myoclonic epilepsy with spasticity and
intellectual disability, and hydranencephaly with abnormal
genitalia) have been related to ARX mutations with loss-of-
function (nonsense or missense mutations in the homeobox
domain).7–9 However, ARX mutations with gain-of-function
(expansion of polyalanine tracts, missense mutations outside
the homeodomain, and deletion of exon 5) cause non-malforma-
tion syndromes (e.g., Partington syndrome, non-syndromicmental
retardation, and X-linked infantile spasms syndrome (ISSX) that
include WS and OS). Shinozaki et al. found that expansion of the
ﬁrst polyalanine tract with 11 expanded alanine residues causes
EIEE; however, the insertion of 8 alanine residues into the second
polyalanine tract, the most common type of ARX anomaly, results
in X-linked mental retardation, ISSX, and the Partington syn-
drome.10 The human ARX protein was shown to be a potent
transcriptional repressor, so the expansion of either the ﬁrst or the
second ARX polyalanine tract enhances the transcriptional
repression activity in a manner dependent on the length of the
alanine expansion.11 The longer expansion of the polyalanine tract
causes the more earlier and severe phenotype (EIEE/OS), while the
shorter expansion leads to the less severe and later-onset WS.12
Pleiotropic mutations of the ARX gene cause a variety of
phenotypes that are considered to share a common pathological
mechanism related to the structural and functional disturbance of
interneurons, called ‘interneuronopathies’.13,14 This hypothesis
was supported by experimental data (from ARX-knockout mice)
demonstrating that ARX protein deﬁciency results in the loss of
GABAergic interneurons and anomalous distribution of residual
cells in the cortex and basal ganglia.15 Consequently, GABAergic
network dysfunction seems to play a crucial role in the
pathogenesis of SB and the hypsarrhythmic pattern. The
syntaxin-binding protein 1 (STXBP1) or the MUNC18-1 gene
encodes a neuron-speciﬁc protein that is essential for synaptic
vesicle release.16,17 Many authors have considered STXBP1
haploinsufﬁciency as a possible cause of EIEE. Saitsu et al.
described several mutations (frameshift, nonsense, splicing, and
recurrent missense mutations) in patients with EIEE suggesting
that STXBP1 aberration is associated with the early onset of
epilepsy and invariable development of mental retardation and
might be an important cause for cryptogenetic EIEE.18,19 It remains
to elucidate how haploinsufﬁciency of STXBP1 leads to EIEE. The
authors did not identify any brain malformation in the 5 subjects
with EIEE who had STXBP1 defects, but they described extensive
neuronal cell death in the brainstem that, in addition to the
impaired synaptic vesicle release, might contribute to EIEE
pathogenesis. In addition, a recent study showed that mutations
in STXBP1 are not limited to patients with OS but are also present in
patients with early-onset epileptic encephalopathy, which does
not ﬁt into either OS or WS. This strongly supports the hypothesis
that mutations in STXBP1 could cause many types of epileptic
disorders.20,21
3. Early myoclonic encephalopathy
Early myoclonic encephalopathy (EME) (OMIM #609304) is an
age-related, generalised epilepsy of non-speciﬁc etiology22 and
was ﬁrst described by Aicardi and Goutieres in 1978.23 EME is
characterised by the very early onset of fragmentary and erratic
myoclonias and is frequently associated with partial seizures.
Interictal EEG shows an SB pattern, with a short burst and a long
suppression, enhanced by sleep.24,25 Unlike the OS, EME shows nospeciﬁc evolution with age, and the prognosis is very poor with no
effective treatment.4,26 The etiology of EME remains unknown in
majority of the patients. It has been hypothesised that genetic
factors and/or inborn errors ofmetabolism play a crucial role in the
pathogenesis of this encephalopathy, since patients with EME and
several inborn errors ofmetabolism (e.g., methylmalonic acidemia,
nonketotic hyperglycinemia, propionic aciduria, Zellweger syn-
drome, D-glyceric acidemia, sulﬁte and xanthine oxidase deﬁcien-
cy, and Menkes disease) have been reported, with a high incidence
of familial cases.24,26–29 Ohtahara and Yamatogi argued that EME
could be due to extensive cortico-subcortical dysfunction as a
consequence of multiple severe metabolic disorders rather than a
speciﬁc genetic abnormality.4 Computed tomography and mag-
netic resonance imaging seldom show abnormalities in the early
stage of the disease, which may appear several months later.
Molinari et al. identiﬁed a monozygous missense mutation
(p.Pro206Leu) in exon 8 of the SLC25A22 gene (solute carrier family
25 member 22; also known mitochondrial glutamate carrier 1
[GC1]) in 4 children with EME.30 The SCL25A22 gene is mapped on
chromosome 11p15.5 and encodes a mitochondrial glutamate/H+
symporter.31 Functional analyses of ﬁbroblasts have supported the
hypothesis that this mutation altered an amino acid (proline 206)
that is probably a residue strongly implicated in glutamate
transport. Furthermore, expression studies pointed out that
SLC25A22 gene expression is limited to the brain, especially in
those regions involved in the genesis and control of myoclonic
seizures, such as substantia nigra,32,33 the cranial nerves nuclei III,
the red nuclei, and olivary complexes.34,35 In addition, Berkich
found that SLC25A22 is more abundant in astrocytes than in
neurons, so a defect in this protein may cause glutamate
accumulation in the astrocyte cytosol and glutamate liberation
in the synaptic cleft, which may be involved in the generation of
epileptic-like discharges in the brain.36 Recently, Molinari
described a new homozygous missense mutation in the SLC25A22
gene of an Algerian boy with severe epileptic encephalopathy
associated with SB pattern on EEG and brain abnormalities on
MRI.37 The authors detected a homozygous substitution
(p.Gly236Trp) that led to the change of a highly conserved residue
within the V helix of the internal channel. The complete loss of the
uniport and transport activity of the SLC25A22 mutant protein
demonstrated that the G236 residue is crucial for SLC25A22
activity, even if in vitro functional expression analyses in
Escherichia coli showed that it had no functional transport activity.
Then, how mutations in SLC25A22 cause epilepsy remains an
unsolved question, but these ﬁndings suggest that defective GC1
function could result in a severe alteration of glutamate metabo-
lism in glial cells and lead to alteration of normal brain function,
especially neuronal excitability.
4. Benign familial neonatal seizures, benign familial neonatal/
infantile seizures, and benign familial infantile seizures
Benign familial seizures include benign familial neonatal
seizures (BFNS), benign familial neonatal/infantile seizures
(BFNIS), and benign familial infantile seizures (BFIS) and are
classiﬁed on the basis of the age of onset. BFNS (also known as
benign familial neonatal convulsions or benign familial epilepsy
type 1; OMIM#121200), the ﬁrst identiﬁed central nervous system
channelopathy and the best recognised disease model for
genetically determined human epilepsies, is a rare, monogenic,
autosomal dominant, and benign familial epilepsy syndrome.38 It
is characterised by unprovoked and brief cluster of focal tonic–
clonic convulsions occurring within the ﬁrst days of life and
frequently ﬂowing into status epilepticus. In addition, apnoeic
spells and generalised seizures may occur. No speciﬁc EEG trait
characterises BFNS: interictal EEG ismost commonly normal, and if
F. Nicita et al. / Seizure 21 (2012) 3–116present, anomalies are usually transient.39,40 Majority of the
individuals with BFNS can be kept seizure-free by using
phenobarbital. Seizures disappear spontaneously within 2 months
of life. However, about 10–15% of the children with BFNS develop
seizures later in life, with a variable age of onset and duration; in
this eventuality, seizures are mainly generalised tonic or tonic–
clonic seizures, and EEG may be characterised by centrotemporal
spikes and sharp waves or benign epilepsy with centrotemporal
spikes.41 In addition, some affected children will suffer from
recurrent febrile seizures or photosensitive myoclonic epilepsy.
BFNS is rarely associated with peripheral nerve hyperexcitability
(myokymia),42 therapy-resistant epileptic encephalopathy shortly
after birth, and a variable degree ofmental retardation.43,44 BFNS is
linked tomutations in the KCNQ2 and KCNQ3 genes,45–48 which are
members of a family of voltage-gated potassium channel genes
(KCNQ1–5). KCNQ2 and KCNQ3 are predominantly expressed in the
brain,49 mainly in the hippocampus, temporal cortex, cerebellar
cortex, andmedulla oblongata, from late foetal life to early infancy,
coinciding with the time in which BFNS occurs.50,51 They encode
the voltage-gated Kv7.2 and Kv7.3 channels that produce a
neuronal muscarinic-regulated potassium current (M-current), a
slow activating non-inactivating potassium current important in
the modulation of the resting membrane potential. This action
limits the repetitive ﬁring of many neurons. More than 60
mutations have been described in the BFNS families, with the
majority involving KCNQ2. Approximately half of the KCNQ2
mutations described in BFNS are truncations, splice-site defects, or
deletions or insertions of a small number of bases that cause
frameshifts; about 60% of these mutations are in the C-terminus
and are predicted to cause truncation of the C-terminus with
haploinsufﬁciency.43,52–56 Missensemutations have been reported
in KCNQ3. No major phenotypic differences are observed between
patients with BFNS caused by a KCNQ2 mutation and those with
BFNS caused by a KCNQ3mutation. Because of the small number of
families with BFNS, genotype–phenotype correlations are specu-
lative.57 Penetrance is incomplete (85%); anticipation has not been
observed.38 The majority of newborns diagnosed with BFNS have
an affected parent; however, sporadic BFNS has also been reported.
In BFNIS (OMIM#607745), seizures appear in neonates, and in BFIS
(OMIM #601764), they begin between the 3rd and the 12thmonth
of life. Seizures are usually of the partial type, with or without
secondary generalisation. Mutations in the voltage-gated sodium
channel alpha 2 subunit (SCN2A) have been reported in BFNIS58
and BFIS.59,60 Increased sodium current, derived from the gain-of-
function of the sodium channel and explaining a neuronal
hyperexcitability resulting in seizures, has been reported in
BFNIS.61 Benign infantile seizures may also be associated with
paroxysmal dyskinesia, a movement disorder in the form of
choreoathetosis or dystonia, generating the infantile convulsions
with choreoathetosis (ICCA) syndrome. The ICCA syndrome is
inherited in an autosomal dominant fashion and is linked to
mutations of the 16p12-q12 chromosome, but the ICCA gene has
not been mapped: this critical area displays complicated genomic
architecture and is the site of deletions and duplications associated
with other diseases.62
5. Genetic epilepsy with febrile seizures plus and DS?
Genetic epilepsy with febrile seizures plus (GEFS+) (OMIM
#604233) is a familial, autosomal dominant epileptic syndrome
with a large pattern of intrafamilial and extrafamilial phenotypic
variability. Patients with GEFS+ may suffer from febrile seizures
(FS) after the 6th year of age (called febrile seizures plus [FS+]) and
afebrile myoclonic, absence, atonic, or partial seizures may
appear.63 FS and FS+ represent the milder form of GEFS+, whereas
severe myoclonic epilepsy of infancy (SMEI) or the DS (OMIM#607208) represent the most severe form. SMEI is an epileptic
encephalopathy that starts during the ﬁrst year of life, especially
around the 6th month, with recurrent and long-lasting febrile
seizures, also known as febrile status epilepticus. Drug-resistant
myoclonic, complex partial, and atypical absence seizures can
appear after 12 months of life. Hot water seizures and photosensi-
tivity are present in about 50% of the patients.64 Regression of the
normally acquired mental capacities may start from the 2nd year,
often related to episodes of status epilepticus.63–65 Interictal
myoclonus, ataxia, and pyramidal signs may complete the clinical
picture. Japanese authors described patients with incomplete SMEI
phenotype and have named these variants as borderline severe
myoclonic epilepsy of infancy (SMEB) and intractable childhood
epilepsy with generalised tonic–clonic seizures (ICE-GTC).66,67 In
GEFS+, SMEI, SMEB, and IGE-GTC, mutations in the voltage-gated
SCN1A gene have been discovered. The SCN1A gene (chromosome
2q24.3) is mainly expressed in the cerebral tissue and is implicated
in the generation and propagation of action potentials.2 About 10%
of the GEFS+ patients have SCN1A mutation. In SMEI patients,
mutations in the encoding exons, which are de novo in 95%, are
present in about 80% of the cases, and they includemissense (39%),
nonsense (22%), frameshift (19%), splice-site (10%), genomic
rearrangements (deletions, duplications, ampliﬁcations, and
translocations) (7%), in-frame deletions (2%), and other types
(silent and complex mutations) (1%) of mutations.68,69 Recently,
the ﬁrst cases of microdeletion limited to the SCN1A noncoding
exons located at 50 promoter region, with the coding sequence
preserved, have been found, indicating the critical involvement of
this upstream region in the molecular pathology of DS.70
Functional studies in animal models with SMEI suggest that
recurrent seizures and ataxia can result from a cell-speciﬁc
reduction of sodium current in interneurons and Purkinje
neurons.2 Genotype–phenotype correlations showed that a severe
clinical picture (e.g., SMEI) is more frequently observed in
association with nonsense mutations, which generate a truncated
alpha subunit, and missense mutations affecting the pore-forming
region (S5–S6), which modify the amino acid polarity, and
consequently, the sodium current. A recent large genotype–
phenotype study of patients with SCN1A mutations revealed that,
compared to missense mutations, truncating mutations were
associated with earlier mean onset of prolonged seizures,
myoclonic seizures, and atypical absence seizures.71 In contrast,
missense mutations in GEFS+ are usually located outside the pore-
forming region.2,72 Some case reports have shown that nonsense
mutations can be associated with phenotypes less severe than
SMEI, such as GEFS+.70 In SMEB or ICE-GTC, missense mutations
are more frequently found.68 It is a common opinion that several
factors may account for the large pattern of phenotypic heteroge-
neity. In particular, stochastic events during development,
environmental factors (e.g., viral infections and vaccination), and
genetic factors (e.g., anomalies in modiﬁer genes, mosaicisms, and
the timing of mutagenesis) may inﬂuence the ﬁnal phenotype of
patients carrying SCN1A anomalies.73–76 It has been recently
reported that diphtheria–tetanus–pertussis vaccination might
trigger the earlier onset of DS in children who, because of an
SCN1A mutation, are destined to develop the disease, without
inﬂuencing other clinical aspects (e.g., intellectual outcome and
subsequent seizure type).77 Regarding genetic factors, studies on
the mousemodel for GEFS+ carrying SCN1Amutations have shown
that voltage-gated ion channel variants in SCN2A, SCN8A, and
KCNQ2 can modify the phenotype (‘modiﬁer genes’), inﬂuencing
clinical presentation and severity.78 Several authors have reported
mutations in SCN1A in the form of mosaicism as an important
cause of familial variability (e.g., SMEI children who have inherited
mutations from asymptomatic or slightly affected parents). In a
recent study, mosaicismwas found in 7% of the families with DS.79
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sensitive and has a critical threshold with a phenotype depending
on the percentage of functional sodium channels: in case of
haploinsufﬁciency (50% functional Na+ channel reduction) SMEI is
observed; in case of mosaicism (<50% functional Na+ channel
reduction), milder phenotypes are reported. However, these
observations are derived from blood lymphocytes and not from
neurons.80–84 Finally, a twin study showed that de novomutations
in SCN1A may occur at any time, from the premorula stage of the
embryo (causing disease in the subject) to adulthood (with
mutations in the germ-line cells of parents causing disease in the
offspring).85 Till now, in DS, hundreds of mutations were found in
SCN1A, while only few mutations were identiﬁed in the paralog
gene SCN2A, which encodes the alpha2 subunit, associated with
BFNIS and BFIS and other various intractable childhood epilep-
sies.86,87 Mutations of the SCN1B gene and the GABA receptor
gamma2 subunit (GABRG2) gene were identiﬁed in a few families
with the GEFS+ spectrum.88,89
6. Epilepsy and mental retardation limited to females
Epilepsy and mental retardation limited to females (EFMR)
(OMIM #300088) is an epileptic encephalopathy ﬁrst described in
197190 and then in 1997.91 In EFMR, generalised febrile seizures
start around the ﬁrst year of age. Then afebrile partial, absence, and
myoclonic seizures may appear. Episodes of febrile or afebrile
status epilepticus are also possible. Mental abilities are normally
acquired at the time of the ﬁrst seizures, but successively, slowing
of psychomotor development with different degrees of mental
retardation is observed. Behavioural problems can manifest as
autistic, obsessive, or aggressive features.92 The gene responsible
for EFMR, the PCDH19 gene, has been recently discovered.93,94
PCDH19, located on chromosome Xq22, encodes protocadherin 19,
a protein with an unclear biologic role: the gene is expressed in the
developing brain and may take part in neuronal connection and
signal transduction. The genetic mechanism underlying the
phenotypic expression of EFMR has not been completely elucidat-
ed. As speciﬁed by the name, EFMR affects the females and spares
the males. Males are obligate carriers and do not develop the
phenotype. Different mechanisms have been hypothesised to
explain this pattern of inheritance: a dominant negative effect of
the mutant protein in carrier females or the presence of a
compensatory factor in males or the pathogenetic presence of
mosaicism for the PCDH19 gene in females (due to the random X
inactivation process) compared to the homogeneous expression of
the PCDH19 mutated gene in males.93 This last mechanism, called
‘cellular interference’, which assumes that only the co-existence of
PCDH19-positive and PCDH19-negative cells is pathogenic, appears
to be more probable. In addition, unrelated females with de novo
PCDH19 mutations have been described, highlighting the impor-
tance of testing PCDH19 in females with early-onset epilepsy,
intellectual impairment, and autistic features, regardless of family
history.90 It is evident that DS and EFMR share clinical features, but
it is actually discussed if PCDH19 is a newgene for DS or if EFMR is a
DS-like epileptic encephalopathy ‘per se’.94 From the case series
available to date, several clinical differences have been highlight-
ed: EFMR seems to have a slightly older age of onset, no
photosensitivity, less frequent status epilepticus and absence
and myoclonic seizures, typical clusters of brief seizures, frequent
focal seizures, and lastly, a milder degree of developmental
regression and an easier control of epileptic events.94–96 Another
recent study on related and unrelated patients with PCDH19
mutations have shown how the epileptic phenotypemay be highly
variable between families but also within affected members of the
same family. In addition, this study has expanded the clinicalspectrum of PCDH19-related epileptic disorders, since a family
with GEFS+ features carried PCDH19 anomalies.97
7. Issx-rett syndrome
The Rett syndrome (RTT) (OMIM #312750) is a progressive
neurodevelopmental disorder characterised by acquired micro-
cephaly, repetitive stereotyped hand movements, regression of
mental capacities with communication dysfunction, loss of
acquired speech, and cognitive impairment. Approximately 80%
of the patients with RTT develop epilepsy.98 Mutations in the
methyl-CpG-binding protein 2 (MECP2) gene, located on Xq28,
account for 80% of the patients with RTT. MECP2 mutations are
usually lethal inmales, but livingmaleswith RTT carrying different
types of mosaicism or mild forms of MECP2 gene mutations have
been reported.99 Besides the classical form, different variants of
RTT exist such as the congenital form, the ‘forme fruste’ and late
childhood regression, and the infantile onset seizures type
(Hanefeld syndrome). Mutations in the cyclin-dependent kinase-
like 5 (CDKL5/STK9) gene have been reported in patients with
phenotype overlapping that of Hanefeld syndrome and ISSX
(OMIM #308350).100–102 The CDKL5-associated phenotype are
characterised by onset of encephalopathy with infantile spasms in
the ﬁrst fewmonths of age, late drug-resistant seizures, hypotonia,
and RTT-like features.103
CDKL5 and MECP2 play an important pathogenic role in the
genesis of RTT since cyclin-dependent kinase phosphorylates
MECP2. Clinical overlapping features between patients withMECP2
and CDKL5 mutations are believed to depend on the same
molecular pathway and the similar temporal and regional patterns
of expression during development shared by the 2 proteins.104
Although MECP2 is the only known substrate of CDKL5, epileptic
seizures associated with CDKL5 mutations may result from
abnormal phosphorylation of other unidentiﬁed proteins. In
addition, differences among patients with CDKL5-associated
encephalopathy have been reported, and this clinical heterogene-
ity in unrelated patients may be due to genetic factors such as X-
inactivation of the same CDKL5 gene and polymorphisms affecting
the target genes of CDKL5 and/or MECP2.103
8. Early-onset absence epilepsy
Absence seizures are epileptic manifestations that may start in
children typically between the 4th and the 10th year of age
(childhood absence epilepsy [CAE]). Less commonly, absence
seizures may arise before the 4th year of age (early-onset absence
epilepsy [EOAE]) and may be associated with other neurological
disorders (other types of seizures, developmental delay, and
movement disorders).105 Mutations in 3 different genes have been
reported in children with absence seizures: anomalies of the
GABRG2 gene have been described in patients with febrile seizures
and CAE106,107 and mutations in the SCN1B and SCL2A1 genes have
been reported in children with EOAE, with108 or without109 febrile
seizures. A deletion of 5 amino acids in the extracellular
immunoglobulin-like domain of the SCN1B gene, with potential
loss of function of the gene, has been described in a single family
with FS+ and EOAE. The authors hypothesised that SCN1B
mutations, more often associated with GEFS+, may have a role
in the elicitation of absence seizures. The SCL2A1 gene encodes
glucose transporter type 1 (GLUT1), a glucose transporter across
the blood-brain barrier. SCL2A1 is responsible for the GLUT1
deﬁciency syndrome (infantile-onset epilepsy with heterogeneous
type of seizures, complex movement disorders, ataxia, intellectual
disability, macrocephaly, and diagnostic hypoglycorrhachia with
normoglycaemia and a cerebrospinal ﬂuid/blood glucose ratio of
less than 0.4)110 and a large milder phenotypic spectrum
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normal mental capacities, and seizures (in particular absence
seizures).111 Starting from these observations, Suls et al. have
found mutations in the SCL2A1 gene in 4 (12%) of a cohort of 34
children with EOAE (3 exonic missense mutations and 1 intronic
splice-site mutation). The intronic mutation creates a new splice
acceptor site, generating an aberrant SLC2A1 transcript; the
missense mutations reduce the transport capacity of GLUT1,
probably without affecting glucose binding, protein stability, or
intracellular transport mechanisms. Clinically, the mutated
patients presented with absence seizures, with onset before 4
years of age, as the predominant seizure type, in association with
generalised tonic–clonic seizures (3/4) and myoclonus (1/4). The
epilepsy was easily controlled in some and refractory in others;
intellect ranged from normal to moderately impaired. Subtle
paroxysmal dyskinesiawas observed in 1 case. Thus, the earlier age
of onset is the sole feature that can help distinguish the seizure
phenotype of EOAE fromCAE. In addition, the authors preliminarily
reported a marked reduction of epileptic activity on EEG in 2 of the
mutated patients receiving a ketogenic diet. In fact, it was noted
that the ketogenic diet may control seizures in cases of GLUT1
deﬁciency syndrome.109 Lastly, a recent study performed by the
same group of authors demonstrated that the epileptic phenotypic
spectrum of GLUT1 deﬁciency is greater than that recognised
previously. In fact, the authors have reported 12 patients with
SCL2A1 mutations and epilepsy, including absence epilepsies with
onset from early childhood to adult life, and various common
forms of idiopathic generalised epilepsy.112
9. Juvenile myoclonic epilepsy
Juvenile myoclonic epilepsy (JME) or the Janz syndrome (OMIM
#254770) is characterised by myoclonic seizures without loss of
consciousness. Myoclonic seizures usually start around puberty,
involve mainly the arms, and can develop in the form of myoclonic
jerks, which can cause sudden fall. In addition, generalised tonic–
clonic and absence seizures may appear. Mutations of several
genes have been reported in patients with JME. Mutations of the
EF-hand motif containing 1 (EFHC1) gene has been related to
classical JME,113 but anomalies of the GABAA receptor alpha 1
subunit (GABRA1) and the voltage-gated chloride channel CIC-2
(CLCN2) genes have been discovered in cases of idiopathic
generalised epilepsy, including JME.114–116 Higher frequency of
CHRNA4 1674(+11)C>T polymorphism has been observed in
patients with JME, suggesting that the CHRNA4 may be one of
the candidate genes for this epileptic syndrome.117 The EFHC1 gene
encodes the EF-hand-containing calcium binding protein, which
most likely plays a role in calcium homeostasis. GABAA receptors
are ligand-gated chloride channels, which carry out inhibitory
functions in the central nervous system.118 The GABAA receptor is a
heteropentameric protein complex made of 19 different classes of
subunits (a1–6, b1–4, g1–3, d, e, u, p, and r1–2). The majority of
the mutations occurring in one of these subunits reduce the
inhibitory chloride currents.118 Chloride currents are also altered
in case of CLCN2 gene mutations, since anomalies of the CIC-2
channels determine the impairment of chloride efﬂux, with
intracellular accumulation of chloride; this may lead to im-
pairment of GABAergic neuronal transmission.116,118
10. Autosomal dominant nocturnal frontal lobe epilepsy
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
is characterised by brief (5 s–5 min)motor hyperkinetic seizures of
frontal origin with tonic or dystonic features presenting in clusters
during the night in non-REM sleep and most commonly, in stage 2
sleep. Daytime seizures may rarely occur. ADNFLE usually beginsin the ﬁrst 2 decades and is lifelong, but with older age, seizures
may become milder and less frequent.119,120 The term ADNFLE
should only be used in case of presence of the typical clinical
features associated with a positive family history for other affected
individuals and/or a mutation in either CHRNA4 (ADNFLE type 1;
OMIM #600513), CHRNB2 (ADNFLE type 3; OMIM #695357), or
CHRNA2 (ADNFLE type 4; OMIM #610353) genes, since the clinical
features of ADNFLE are indistinguishable from those of nonfamilial
nocturnal frontal lobe epilepsy.121–123 The estimated penetrance is
70%. Mutations in CHRNA4, CHRNB2, or CHRNA2, which encode the
neuronal acetylcholine receptor (a4, b2, and a2 subunit,
respectively) can be found in around 10–20% of the individuals
with a positive family history but only in around 5% of the
individualswith a negative family history.124–127 The pore-forming
M2 transmembrane segments are affected by thesemutations, and
increased acetylcholine sensitivity is believed to be themain defect
of the mutation.1 In addition, mutations in the corticotropin-
releasing hormone (CRH) gene of locus 15q24, which contains the
CHRNA3, CHRNA5, and CHRNB4 genes, have been identiﬁed in
patients with ADNFLE.
11. Autosomal dominant partial epilepsy with auditory
features or autosomal dominant lateral temporal epilepsy
This inherited epileptic syndrome was ﬁrst described and
named by Ottman in 1995 as autosomal dominant partial epilepsy
with auditory features (ADPEAF), since partial seizures with
auditory features arising from the temporal lobe are the main
manifestations.128 However, considering that ictal symptoms
originating from the temporal lobe are not limited to auditory
features, the termhas been changed to autosomal dominant lateral
temporal epilepsy (ADLTE) (OMIM#600512).129 Seizures in ADLTE
are described as focal, typically with auditory auras (e.g., ringing,
singing, and whistling), with or without temporal sensory
symptoms (e.g., aphasia, vertigo, and olfactory and visual
phenomena), with a possible secondary generalisation with
tonic–clonic manifestations. Seizures, which usually begin in
young patients, may be triggered by exterior stimuli (e.g., noise or
sound) and are considered to be benign and easy to control with
antiepileptic drugs.130 The leucine-rich glioma-inactivated 1 (LGI1)
gene has been identiﬁed as the cause of familial (ADLTE) and
nonfamilial partial epilepsy with auditory features (called
idiopathic partial epilepsy with auditory features [IPEAF]).
Mutations in LGI1 have been found in about 50% of the ADLTE
patients and in about 2% of the IPEAF patients,131–134 and the
penetrance of the mutations is around 67%.135 The LGI1 gene is
located at 10q23.33; it is expressed mainly in the brain, with
neuronal rather than glial predominance. The LGI1 protein product
is not a neuronal ion channel, and itsmutationsmay bemore easily
associated with mechanisms of epileptogenesis. Its biological role,
and in particular, its involvement in neuronal transmission,
remains unclear. The rapidly inactivating Kv1 potassium channel
and ADAM22, a neuronal transmembrane receptor, are associated
with the LGI1 protein, but nomutations in these 2 genes have been
discovered in LGI1-negative ADLTE families.136,137 Finally, a recent
hypothesis suggests that the LGI1 gene may be implied in
structural brain development, and its mutations may result in
cortical abnormalities of the temporal lobe, which are not visible
on standard MRI but may be identiﬁed by new imaging techniques
such as diffusion tensor imaging.138
12. Conclusions
In this review, we have summarised the rapid progress in the
ﬁeld of genetics, which allowed the identiﬁcation of epilepsy-
causing gene mutations underlying idiopathic epilepsies and
F. Nicita et al. / Seizure 21 (2012) 3–11 9epileptic encephalopathies and resulted in the improvement of
classiﬁcation, prognosis, and counselling. An intriguing and
hopeful challenge is the engine of targeted antiepileptic drugs,
which may act on the basis of a well-known gene anomaly. For
example, ezogabine (retigabine) is a new drug for adjunctive
therapy of partial-onset seizures with a novel mechanism of action
that consists of the opening of neuronal voltage-gated potassium
KCNQ2 and 3 channels, thus promoting membrane repolarisation
and opposing rapid repetitive discharges. However, it should be
kept in mind that monogenic determined epileptic syndromes
account only for a minority of the idiopathic epilepsies, and
consequently, genetic tests should be performed after accurate
clinical selection of families and probands. It is hoped that, in the
near future, other epilepsy-causing genes will be discovered and
other genetic and non-genetic factors responsible for the epileptic
phenotypes will be clariﬁed.
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